The Asia Pacific Rat Model Market should witness market growth of 8.5% CAGR during the forecast period (2022-2028).
The expansion of the market is attributable to an increase in the demand for pharmaceuticals, which has encouraged the expansion of research for improved health. In addition, the development of genetic engineering techniques has enabled the use of genetic engineering in rat models. During pre-clinical and clinical studies, these genetically engineered models (GEM) are utilized extensively to find and validate the pharmacodynamics and pharmacokinetics of medicines.
In the coming years, the market will be driven by the rising consumption of pharmaceuticals and the ensuing rise in drug testing. In addition, major advancements in various facets of the rat model production process, including technology, such as enhanced fertilized egg injection as well as ovulation stimulation techniques, will contribute to the expansion of the sector. These advancements in genome editing techniques have allowed for the creation of more complex genetically modified models, which will stimulate market expansion. The continued use of rats in experimental techniques has increased interest in the ethical treatment of these cherished animals.
Numerous rat strains have been developed through the selective breeding of animals exhibiting the desired phenotype, resulting in an extensive array of genetic models of pathologically complicated, polygenic features, the vast majority of which are quantifiable. Intriguingly, these strains also possess characteristics that were not selected for. As with the qualities selected, the majority of these phenotypes are polygenic. All of these phenotypes can serve as models for human features or disorders, meaning that the genes responsible for these traits or diseases must be found.
Because of the rise in the number of initiatives as well as augmented investments from governments for overall research and development of drugs using animal models, in addition to the rise in the implications of mouse clinical trials for more projected outcomes, the animal model market in Asia-Pacific presents key players operating in the market with lucrative opportunities. Owing to the fact that the R&D industry of regional countries, like India, is expanding at an exponential rate. In addition to this, a spike in the attention of major manufacturers on increasing their geographical presence in growing Asia-Pacific countries in order to acquire a high market share is likely to boost the growth of the animal model market in the region. Hence, this factor is driving the growth of the regional rat model market.
The China market dominated the Asia Pacific Rat Model Market by Country in 2021; thereby, achieving a market value of $113.1 million by 2028. The Japan market is registering a CAGR of 7.8% during (2022-2028). Additionally, The India market would showcase a CAGR of 9.1% during (2022-2028).
Based on Technology, the market is segmented into CRISPR/CAS & Others, Nuclear transferase, and Embryonic Stem Cell & Microinjection. Based on Type, the market is segmented into Outbred, Hybrid, Knockout, Inbred, Immunodeficient, and Conditioned. Based on Service, the market is segmented into Breeding, Genetic testing, Cryopreservation, Re-derivation, and Quarantine Depending & Others. Based on Application, the market is segmented into Toxicology, Oncology, Immunology, and Neurology & Others. Based on End-use, the market is segmented into CROs, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Inotiv, Inc., genOway, Janvier Labs, Taconic Biosciences, Inc. (H.I.G. Capital), TransViragen, Inc., Biomedical Research Models, Inc. (Biomere) and Cyagen Biosciences.
The expansion of the market is attributable to an increase in the demand for pharmaceuticals, which has encouraged the expansion of research for improved health. In addition, the development of genetic engineering techniques has enabled the use of genetic engineering in rat models. During pre-clinical and clinical studies, these genetically engineered models (GEM) are utilized extensively to find and validate the pharmacodynamics and pharmacokinetics of medicines.
In the coming years, the market will be driven by the rising consumption of pharmaceuticals and the ensuing rise in drug testing. In addition, major advancements in various facets of the rat model production process, including technology, such as enhanced fertilized egg injection as well as ovulation stimulation techniques, will contribute to the expansion of the sector. These advancements in genome editing techniques have allowed for the creation of more complex genetically modified models, which will stimulate market expansion. The continued use of rats in experimental techniques has increased interest in the ethical treatment of these cherished animals.
Numerous rat strains have been developed through the selective breeding of animals exhibiting the desired phenotype, resulting in an extensive array of genetic models of pathologically complicated, polygenic features, the vast majority of which are quantifiable. Intriguingly, these strains also possess characteristics that were not selected for. As with the qualities selected, the majority of these phenotypes are polygenic. All of these phenotypes can serve as models for human features or disorders, meaning that the genes responsible for these traits or diseases must be found.
Because of the rise in the number of initiatives as well as augmented investments from governments for overall research and development of drugs using animal models, in addition to the rise in the implications of mouse clinical trials for more projected outcomes, the animal model market in Asia-Pacific presents key players operating in the market with lucrative opportunities. Owing to the fact that the R&D industry of regional countries, like India, is expanding at an exponential rate. In addition to this, a spike in the attention of major manufacturers on increasing their geographical presence in growing Asia-Pacific countries in order to acquire a high market share is likely to boost the growth of the animal model market in the region. Hence, this factor is driving the growth of the regional rat model market.
The China market dominated the Asia Pacific Rat Model Market by Country in 2021; thereby, achieving a market value of $113.1 million by 2028. The Japan market is registering a CAGR of 7.8% during (2022-2028). Additionally, The India market would showcase a CAGR of 9.1% during (2022-2028).
Based on Technology, the market is segmented into CRISPR/CAS & Others, Nuclear transferase, and Embryonic Stem Cell & Microinjection. Based on Type, the market is segmented into Outbred, Hybrid, Knockout, Inbred, Immunodeficient, and Conditioned. Based on Service, the market is segmented into Breeding, Genetic testing, Cryopreservation, Re-derivation, and Quarantine Depending & Others. Based on Application, the market is segmented into Toxicology, Oncology, Immunology, and Neurology & Others. Based on End-use, the market is segmented into CROs, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Inotiv, Inc., genOway, Janvier Labs, Taconic Biosciences, Inc. (H.I.G. Capital), TransViragen, Inc., Biomedical Research Models, Inc. (Biomere) and Cyagen Biosciences.
Scope of the Study
By Technology
- CRISPR/CAS & Others
- Nuclear transferase
- Embryonic Stem Cell & Microinjection
By Type
- Outbred
- Hybrid
- Knockout
- Inbred
- Immunodeficient
- Conditioned
By Service
- Breeding
- Genetic testing
- Cryopreservation
- Re-derivation
- Quarantine Depending & Others
By Application
- Toxicology
- Oncology
- Immunology
- Neurology & Others
By End-use
- CROs
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
- Inotiv, Inc.
- genOway
- Janvier Labs
- Taconic Biosciences, Inc. (H.I.G. Capital)
- TransViragen, Inc.
- Biomedical Research Models, Inc. (Biomere)
- Cyagen Biosciences
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Rat Model Market by Technology
Chapter 4. Asia Pacific Rat Model Market by Type
Chapter 5. Asia Pacific Rat Model Market by Service
Chapter 6. Asia Pacific Rat Model Market by Application
Chapter 7. Asia Pacific Rat Model Market by End-use
Chapter 8. Asia Pacific Rat Model Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
- Inotiv, Inc.
- genOway
- Janvier Labs
- Taconic Biosciences, Inc. (H.I.G. Capital)
- TransViragen, Inc.
- Biomedical Research Models, Inc. (Biomere)
- Cyagen Biosciences
Methodology
LOADING...
